BioTelemetry (BEAT) Getting Somewhat Favorable Press Coverage, Report Finds

Media coverage about BioTelemetry (NASDAQ:BEAT) has been trending somewhat positive this week, according to AlphaOne Sentiment Analysis. The research firm, a service of Accern, identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioTelemetry earned a news sentiment score of 0.10 on AlphaOne’s scale. AlphaOne also assigned headlines about the medical research company an impact score of 47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Alpha One Sentiment’s rankings:

Insider Buying and Selling by Quarter for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ BEAT) traded up 0.8486% on Tuesday, hitting $29.6999. 227,741 shares of the stock traded hands. The company’s 50 day moving average price is $29.22 and its 200-day moving average price is $26.25. BioTelemetry has a 12-month low of $14.72 and a 12-month high of $34.00. The stock has a market capitalization of $851.05 million, a P/E ratio of 18.5508 and a beta of 0.65.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $55.88 million during the quarter, compared to analysts’ expectations of $55.11 million. BioTelemetry had a return on equity of 19.87% and a net margin of 22.77%. Analysts predict that BioTelemetry will post $0.89 EPS for the current year.

Several equities analysts have recently issued reports on BEAT shares. Zacks Investment Research raised shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Tuesday, May 2nd. Dougherty & Co lifted their price objective on shares of BioTelemetry from $30.00 to $37.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $30.20.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2656308/biotelemetry-beat-getting-somewhat-favorable-press-coverage-report-finds.html.

In other news, Director Robert J. Rubin sold 15,000 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $28.14, for a total value of $422,100.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.60% of the company’s stock.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:BEAT”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.